Joseph Haraszti
Psychiatry · Pasadena, CANPI 1316087422
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,480 of the $16,669 with a category attached, or 74.9%. AbbVie accounts for 80.9% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $5,646 and has fallen 91.3% since, to $490 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $102.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$13K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$576
- Johnson & Johnson$236
- Takeda Pharmaceuticals U.S.A., Inc.$180
- Lundbeck LLC$177
- plus $706 from 10 others
Across 4 payments — averaging $1031.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Avanir Pharmaceuticals, Inc.$4K
What the payments were for
- Speaking & faculty fees$12,48075%
- Food & beverage$4,18925%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $13,491 |
| Alkermes, Inc. | 51 | $1,303 |
| Otsuka America Pharmaceutical, Inc. | 24 | $576 |
| Johnson & Johnson | 4 | $236 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $180 |
| Lundbeck LLC | 9 | $177 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $173 |
| Teva Pharmaceuticals USA, Inc. | 1 | $117 |
| Vanda Pharmaceuticals Inc. | 4 | $97 |
| Indivior Inc. | 1 | $95 |
| Almatica Pharma LLC | 4 | $81 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Collegium Pharmaceutical, Inc. | 2 | $28 |
| Ironshore Pharmaceuticals Inc. | 1 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Tris Pharma Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,669 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 12 | $20,390 |
| RexultiBrexpiprazole | 11 | $13,944 |
| Lurasidone Hcl | 20 | $10,133 |
| LamictalLamotrigine | 11 | $7,096 |
| BelsomraSuvorexant | 11 | $4,501 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,412 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 11 | $2,949 |
| VascepaIcosapent Ethyl | 12 | $2,225 |
| Divalproex Sodium ErDivalproex Sodium | 35 | $2,072 |
| Paliperidone ErPaliperidone | 14 | $1,870 |
| Nefazodone Hcl | 11 | $1,812 |
| Selegiline Hcl | 25 | $1,464 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 42 | $1,441 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $1,396 |
| Aripiprazole | 34 | $1,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $173 | $20,39012 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $576 | $13,94411 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $180 | $4,41212 claims |
| AbbVieSynthroid | $13,491 | $84111 claims |
| Almatica Pharma LLCSertraline Hcl | $81 | $22425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Pasadena
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.